Free Trial

Noble Financial Upgrades Zomedica (NYSEAMERICAN:ZOM) to "Strong-Buy"

Zomedica logo with Medical background

Zomedica (NYSEAMERICAN:ZOM - Get Free Report) was upgraded by Noble Financial to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports.

Zomedica Stock Up 17.3 %

Shares of ZOM stock traded up $0.02 during trading on Monday, hitting $0.14. The company's stock had a trading volume of 25,571,575 shares, compared to its average volume of 4,687,302. The firm has a market cap of $140.72 million, a PE ratio of -2.05 and a beta of 1.06. Zomedica has a 52 week low of $0.12 and a 52 week high of $0.23.

Institutional Investors Weigh In On Zomedica

An institutional investor recently raised its position in Zomedica stock. Virtu Financial LLC increased its holdings in Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) by 1,585.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 168,773 shares of the company's stock after buying an additional 158,757 shares during the period. Virtu Financial LLC's holdings in Zomedica were worth $25,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.95% of the company's stock.

Zomedica Company Profile

(Get Free Report)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.

Further Reading

→ Trump won. Buy this coin now. (From Weiss Ratings) (Ad)

Should you invest $1,000 in Zomedica right now?

Before you consider Zomedica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.

While Zomedica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines